Farmers Branch Dialysis Center is a medicare approved dialysis facility center in Farmers Branch, Texas and it has 24 dialysis stations. It is located in Dallas county at 2280 Springlake Road, Farmers Branch, TX, 75234. You can reach out to the office of Farmers Branch Dialysis Center at (972) 488-1191. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Farmers Branch Dialysis Center has the following ownership type - Profit. It was first certified by medicare in September, 1994. The medicare id for this facility is 452682 and it accepts patients under medicare ESRD program.
| Name | Farmers Branch Dialysis Center |
|---|---|
| Location | 2280 Springlake Road, Farmers Branch, Texas |
| No. of Dialysis Stations | 24 |
| Medicare ID | 452682 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 2280 Springlake Road, Farmers Branch, Texas, 75234 | |
| (972) 488-1191 | |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
| NPI Number | 1316214778 |
| Organization Name | Farmers Branch Dialysis Center |
| Doing Business As | Terrell Dialysis Center, Llc |
| Address | 2280 Springlake Rd Farmers Branch, Texas, 75234 |
| Phone Number | (972) 488-1191 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
| NPI Number | 1629180518 |
| Organization Name | Farmers Branch Dialysis Center |
| Doing Business As | Bio-medical Applications Of Texas, Inc. |
| Address | 2280 Springlake Rd Farmers Branch, Texas, 75234 |
| Phone Number | (972) 488-1191 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 74% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 16% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 10% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 60% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 33% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 7% | 14% |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 65% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 18% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 17% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 62% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 29% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 75% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 25% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 64% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 27% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 48 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 4 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 112 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1030 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Farmers Branch Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 115 |
| Hypercalcemia patient months | 1061 |
| Patients with Serumphosphor | 116 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
| Patients with Serumphosphor greater than 7 mg/dL | 12 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 107 |
| Patient months included in arterial venous fistula and catheter summaries | 723 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 64 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 93 |
| Hospitalization Rate in facility | 179.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 307.1 |
| Hospitalization Rate: Lower Confidence Limit | 113.7 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Farmers Branch Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 20.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 28.9 |
| Readmission Rate: Lower Confidence Limit | 13.7 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Farmers Branch Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .46 (As Expected) |
| SIR: Upper Confidence Limit | 1.25 |
| SIR: Lower Confidence Limit | .12 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Farmers Branch Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 84 |
| Transfusion Rate in facility | 36.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 80.9 |
| Transfusion Rate: Lower Confidence Limit | 18.4 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Farmers Branch Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 491 |
| Mortality Rate in facility | 16.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 21.8 |
| Mortality Rate: Lower Confidence Limit | 12.3 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago
Farmers Branch Dialysis Center Location: 2280 Springlake Road, Farmers Branch, Texas, 75234 Phone: (972) 488-1191 |
News Archive
The Editor-in-Chief of Human Gene Therapy, the first journal devoted to the field of gene therapy, and one of the world's leading experts on gene therapy have co-authored a new editorial, Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy, in response to the news of two deaths in a now-halted gene therapy clinical trial.
The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.
Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer.
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
› Verified 9 days ago